Advertisement

Topics

Search Results for "What Is Lambda Z In Pharmacokinetics"

17:13 EDT 4th May 2016 | BioPortfolio

Matching Channels

Pharmacokinetics

macitentan

Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

Serine Threonine protein kinase C PKC

The serine/threonine protein kinase C (PKC) family consists of at least 11 mammalian isozymes belonging to a larger subclass of protein kinases termed the adenine-guanine-cytosine (AGC) kinases. PK...

Matching News

Eiger BioPharma licenses “Lambda” from Bristol-Myers

USA-based Eiger BioPharmaceuticals has licensed Pegylated Interferon Lambda-1a (Lambda), a novel, well-characterized,…

Eiger Biopharma Licenses an Investigational HVD Therapy from BMS

PALO ALTO, Calif., April 20, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a (“Lambda”), a novel...

Lambda appointed new president

Biospectrum Lambda announces the joining of Dr Tausif Monif as President – Global Operations [Read more]

Eiger licenses lambda to investigate potential therapy for hepatitis delta

Eiger BioPharmaceuticals Inc. announced it licensed pegylated interferon lambda-1a to Bristol-Myers Squibb to investigate the efficacy and safety of the drug as a therapeutic option for the treatment ...

Eiger BioPharmaceuticals to Develop BMS' Lambda for HDV

Eiger BioPharmaceuticals said today it has licensed from Bristol-Myers Squibb (BMS) its Pegylated Interferon Lambda-1a, a first-in-class type III interferon, for study as a monotherapy and combinati...

Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model

Catalytic DNA: Ligating with lambda

BRIEF-Eiger Biopharmaceuticals says license of worldwide rights to Pegylated Interferon lambda-1a from Bristol-Myers Squibb

* Eiger biopharmaceuticals announces license of worldwide rights to pegylated interferon lambda-1a from bristol-myers squibb

Matching PubMed Articles

Evolution of Hematopoietic Cell transplantation for immunoglobulin light chain (AL) amyloidosis.

A 45-year-old male presented to our institution for management of recent diagnosis of lambda light chain AL established on a kidney biopsy that was done to evaluate new onset nephrotic syndrome. The p...

Peginterferon Lambda-1a is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C.

Peginterferon alfa (alfa) increases the risk of autoimmune disease. Peginterferon lambda-1a (Lambda) acts through a receptor with a more liver-specific distribution compared to the alfa receptor. In a...

Biological trait analysis and stability of lambda-cyhalothrin resistance in the house fly, Musca domestica L. (Diptera: Muscidae).

House flies, Musca domestica L., (Diptera: Muscidae), are pests of poultry and have the ability to develop resistance to insecticides. To design a strategy for resistance management, life history trai...

No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects.

Nebivolol, a clinically important antihypertensive drug, mainly metabolized by cytochrome P450 (CYP) 2D6, shows wide interindividual variability in pharmacokinetics. The CYP2D6*10 allele (100C>T; rs10...

Roxithromycin Pharmacokinetics in Hospitalized Geriatric Patients: Oral Administration of Whole Versus Crushed Tablets.

Drug administration as tablets to debilitated elderly patients in crushed form can modify the pharmacokinetic characteristics of the active components. Only scarce information is available on the phar...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement